Table 4.
Comparison of pathway metabolites in CRC and non-malignant bowel conditions.
| Metabolite | Non-Malignant Conditions (n = 126) | CRC (n = 137) | p-Value |
|---|---|---|---|
| Arg [µM] | 147.7 (114–177) | 140.6 (106–174) | 0.495 |
| Cit [µM] | 74.2 (41–116) | 46.6 (36–61) | <0.00001 |
| ADMA [µM] | 0.57 (0.49–0.64) | 0.58 (0.48–0.67) | 0.605 |
| SDMA [µM] | 0.46 (0.40–0.58) | 0.57 (0.47–0.69) | <0.00001 |
| DMA [µM] | 71.2 (57–85) | 63.2 (35–77) | <0.00001 |
Data presented as medians with an interquartile range and analyzed using the Kruskal-Wallis H test. Arg: Arginine; Cit: Citrulline; ADMA: Asymmetric dimethylarginine; SDMA: Symmetric dimethylarginine; DMA: Dimethylamine; CRC: Colorectal cancer. A group of “non-malignant conditions” include patients with adenomas, inflammatory bowel disease, and irritable bowel syndrome.